argenx SE is a Dutch‑Belgian biotechnology company focused on developing and commercializing antibody‑based therapies for immune‑mediated diseases. Founded in 2008, the company operates from the Netherlands and Belgium and is listed on Euronext Brussels and Nasdaq under the ticker ARGX.
Its lead product is efgartigimod, an FcRn antagonist marketed as VYVGART and VYVGART Hytrulo, approved in multiple regions for the treatment of generalized myasthenia gravis; the subcutaneous co‑formulation (Hytrulo) is also approved in the United States for chronic inflammatory demyelinating polyneuropathy (CIDP). argenx maintains a pipeline of antibody programs targeting autoimmune indications across neurology, hematology, and dermatology, progressing candidates through clinical development and working with external partners for manufacturing and commercialization.
Also known as arGEN-X and argenx SE.
Clinical, long-term and real‑world data show deeper ocular MG responses, one‑year efficacy in AChR‑Ab–negative MG, benefits of earlier treatment, CIDP durability and pipeline progress.
Adds FB102, a first‑in‑class anti‑CD122 with clinical proof‑of‑concept in vitiligo and celiac disease; $77 per‑share tender offer completed and merger closed.
Primary endpoint met in Phase 3 ALKIVIA: efgartigimod improved mean Total Improvement Score at Week 52 versus placebo; benefit emerged by Week 4 and was sustained across IMNM and DM.
Commences cash offer of $77 per share; merger to follow subject to HSR clearance and a >50% tender condition.
FB102 shows Phase 1b proof in vitiligo and celiac; Phase 2 in celiac expected H2 2026. Acquisition executed as $77/share cash tender offer; close targeted Q3 2026.
ALKIVIA+ 52‑week data show sustained Total Improvement Score gains; RHO+ shows maintained response after switch to biweekly dosing; safety consistent across indications.
Phase-3 ADAPT SERON: VYVGART showed rapid, significant, sustained improvements across anti-MuSK, anti-LRP4 and triple-seronegative gMG; safety consistent; IV/SC options; access support.
